secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2026-08-03T11:02:13+00:00
Accession:  0001437749-26-025302
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex collaborates with Roche Diagnostics to validate TROP2/PTEN biomarkers for NSCLC
--------------------------------------------------------------------------------

- Collaboration with Roche Diagnostics to validate TROP2 and PTEN biomarkers for patient selection in NSCLC clinical trials.
- Roche's AI-driven companion diagnostic received FDA Breakthrough Device Designation; Genprex will use same TROP2 antibody.
- Validation studies expected to complete by end of 2026, with subsequent integration into NSCLC clinical program.
- Preclinical data: high TROP2 H-scores and low PTEN H-scores predicted response; clinical data correlated with longer PFS.
- Goal to shorten patient identification and recruitment for NSCLC trials, enabling more personalized treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926025302/0001437749-26-025302-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926025302/gnpx20260802_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-025302

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer